9
Table 3. Treatment Recommendations and Follow-up for AMD
Recommended
Treatment
Diagnoses Eligible
for Treatment
Follow-up Recommendations
Intervals Testing
Non-Neovascular AMD
Observation with no
medical or surgical
therapies
Early AMD (AREDS
category 2)
Return
examination at
6–24 months if
asymptomatic
or prompt
examination for
new symptoms
suggestive of
CNV
Fundus photos,
fluorescein
angiography,
or OCT as
appropriate
Advanced AMD with
bilateral subfoveal
geographic atrophy or
disciform scars
Return
examination at
6–24 months if
asymptomatic
or prompt
examination for
new symptoms
suggestive of
CNV
Fundus photos,
fluorescein
angiography, or as
appropriate
Antioxidant
vitamin and mineral
supplements as
recommended in the
original AREDS and
AREDS2 reports
• Intermediate AMD
(AREDS category 3)
• Advanced AMD in
one eye (AREDS
category 4)
Return
examination at
6–18 months if
asymptomatic
or prompt
examination for
new symptoms
suggestive of
CNV
• Monitoring of
monocular near
vision (reading/
Amsler grid)
• Fundus
photography
and/or fundus
autofluorescence
as appropriate
• Fluorescein
angiography
and/or OCT for
suspicion of CNV
Neovascular AMD
Aflibercept
intravitreal injection
2.0 mg as described in
published reports
Macular CNV • Patients should be instructed to
promptly report symptoms suggestive
of endophthalmitis, including eye pain
or increased discomfort, worsening
eye redness, blurred or decreased
vision, increased sensitivity to light, or
increased number of floaters
• Return examination approximately
4 weeks after treatment initially;
subsequent follow-up and treatment
depends on the clinical findings
and judgment of the treating
ophthalmologist
• Monitoring of monocular near vision
(reading/Amsler grid)
